Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) EBITDA Margin (2016 - 2020)

Edesa Biotech's EBITDA Margin history spans 8 years, with the latest figure at 616154.6% for Q3 2020.

  • For Q3 2020, EBITDA Margin changed N/A year-over-year to 616154.6%; the TTM value through Jun 2021 reached 2494161.4%, down 249247168.0%, while the annual FY2020 figure was 1918.9%, N/A changed from the prior year.
  • EBITDA Margin for Q3 2020 was 616154.6% at Edesa Biotech, down from 1542.75% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 752.65% in Q3 2018 and bottomed at 616154.6% in Q3 2020.
  • The 5-year median for EBITDA Margin is 1542.75% (2020), against an average of 63066.94%.
  • The largest annual shift saw EBITDA Margin tumbled -4767247bps in 2017 before it surged 25177005bps in 2020.
  • A 5-year view of EBITDA Margin shows it stood at 997.12% in 2016, then tumbled by -580bps to 6784.2% in 2017, then soared by 111bps to 752.65% in 2018, then plummeted by -233bps to 998.35% in 2019, then crashed by -61617bps to 616154.6% in 2020.
  • Per Business Quant, the three most recent readings for EDSA's EBITDA Margin are 616154.6% (Q3 2020), 1542.75% (Q2 2020), and 1371.98% (Q1 2020).